TCTR20211102004已完成2 期
The efficacy of early HA-330 hemoperfusion for severe and critical COVID-19 patients in a tertiary hospital : A randomized control trial
/A0 个研究点目标入组 24 人开始时间: 2021年11月2日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 15 Years 至 N/A (No limit)（—）
- 性别
- All
入选标准
- •1. COVID-19 patients with age more than 15 year
- •2. Diagnosed as severe or critical COVID-19 infection
- •3. Already received favipirair or remdesivir in combination with corticosteroid (more than 6 mg of dexamethasone or equivalent dose) for more than 24-48 hours
- •4. Hyperinflammatory state including CRP > 75 mg/L , ferritin > 300 ng/ml and serum IL-6 level > 20 pg/ml
- •5. Hypoxemia with PaO2 / FiO2 < 300 and/or oxygen saturation room air < 92 percent and/or Lung infiltration increasing more than 50 percent within 24-48 hours
排除标准
- •1. Patients in terminal states (estimated no more than 24 hours alive)
- •2. Pregnancy
- •3. History of HA-330 catridge or Tocilizumab allergy
- •4. Recent myocardial infarction within 1 month
- •5. Persistent shock more than 12 hours
- •6. Patients who accepted DNR (do not resuscitation)
研究者
相似试验
尚未招募
不适用
Efficacy of HA330 Hemoperfusion in Critically Ill Patients with Severe COVID-19COVIDᆧARDS19ARDSHemoadsorptionILLjPneumoniaTCTR20200409006Excellence Center for Critical Care Nephrology, King Chulalongkorn Memorial Hospital206
招募中
不适用
Hemoperfusion effect in treatment of patients with COVID-19IRCT20110425006280N12Vice President of Research Guilan university of medical sciences20
尚未招募
3 期
se of filters for removal of toxins in acute liver failure patients .CTRI/2019/12/022536Asian Institute of Gastroenterology
已完成
2 期
Hemoperfusion in patients with COVID-19IRCT20150704023055N2Babol University of Medical Sciences10
招募中
2 期
Hemoperfusion in Covid 19IRCT20210718051922N1Shahre-kord University of Medical Sciences60